Dr. Richard Alexander
- Surgical Oncologist
- Peritoneal Specialist
- Expertise:
-
Cytoreductive Surgery
HIPEC - Speciality:
-
Surgical Oncology
- Gender:
-
Male
- Language:
-
English
- Expertise:
-
Cytoreductive Surgery
HIPEC - Speciality:
-
Surgical Oncology
- Gender:
-
Male
- Language:
-
English
Get to Know Dr. H. Richard Alexander
Dr. H. Richard Alexander serves as the chief surgical officer at Rutgers Cancer Institute. He is also a professor of surgery at Rutgers Robert Wood Johnson Medical School.
Dr. Alexander joined Rutgers in 2017 after serving as head of surgical oncology at the University of Maryland School of Medicine and Greenebaum Cancer Center. He treats mesothelioma, appendiceal cancer, colorectal cancer and other abdominal tumors.
In his clinical practice, Alexander offers innovative treatment options for rare cancers such as peritoneal mesothelioma. Over the past two decades, he helped pioneer advances in therapy that are now being used across the country.
Through his research, Alexander developed various treatment combinations that have better managed different abdominal cancers, often targeting molecular mutations. His multidisciplinary approach to mesothelioma treatment often combines intravenous chemotherapy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, which has proven highly effective.
Specialties of Dr. H. Richard Alexander
- Cytoreductive surgery
- Hyperthermic intraperitoneal chemotherapy
- Peritoneal mesothelioma
- Gastrointestinal cancers
- Neuroendicrine tumors
Dr. H. Richard Alexander’s Experience and Medical Education
- Rutgers Cancer Institute of New Jersey
- Greenebaum Comprehensive Cancer Center, University of Maryland
- National Cancer Institute (Surgery branch)
- Memorial Sloan Kettering Cancer Center (Fellowship)
- Walter Reed National Military Medical Center (Residency)
- Georgetown University School of Medicine (M.D.)
Awards and Certifications
- American College of Surgeons (Fellow)
- American Surgical Association (Fellow)
- Society of Surgical Oncology (Fellow)
- Royal College of Surgeons, Glasgow (Honorary member)
- National Institutes of Health Award of Merit
Publications of Dr. H. Richard Alexander
- Adhikary, G. et al. (2018, October 2). Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation. Oncotarget.
- Alexander, H.R. et al. (2018, August 25). Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma. Annals of Surgical Oncology.
- Alexander, H.R. & Burke, A. (2016, February 7). Diagnosis and management of patients with malignant peritoneal mesothelioma. Journal of Gastrointestinal Oncology.
- Alexander, H.R. (2010, January). Surgical Treatment of Malignant Peritoneal Mesothelioma: Past, Present and Future. Annals of Surgical Oncology.